Published : 30 Jul 2015
In the earlier assignments Aagami facilitated deals with 3 global companies of India, for their Australian client. Also couple of assignments involving market research and vendor sourcing were also executed in last 2 years.
Client has yet again placed their trust in Aagami and have assigned Aagami for further partnerships for Dermal Delivery technology and their pipeline assets in derma, pain and anaesthetic.
Client is a research-based biotechnology company that discovers and develops new ways to enhance the delivery, effectiveness, and/or tolerability of proven pharmaceutical, consumer and animal health products. They are publicly listed and headquartered in Melbourne area, Australia.
Using a proprietary drug delivery system based on Vitamin E, client has developed novel and differentiated products that no other company has been able to develop.
In India, Novartis and Themis launched Diclofenac Gel under license from them.
Now our client seeks Partnering of its pipeline products like Tretinoin Gel, Lidocaine Gel, and others. The Technology is also available for Licensing for all Unpartnered indications and molecules.
Dermal Delivery Technology – Features:
This Technology containing products are both on market and in development with global partners like Novartis, Mylan, Themis, Ashland, GNC, Korean Drug Co. Integrated Animal health etc.
Discussions are open for a global or regional license and/or co-development at this stage. Interests and Proposals are being fielded.
Aagami is excited to deliver success once again to its client.